The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Nearly half of US adults admit they’d take one of the newer, injectable weight loss drugs, but that number falls ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...

"Hairspray" actor Harvey Fierstein, who weighed 310 pounds at his heaviest, has lost 120 pounds after taking the weigh-loss ...

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

One lawmaker said the CT Department of Social Services told him the agency wasn’t paying for FDA-approved drugs because of ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

The effects that a pause may have on your body may depend on why you're taking the medication in the first place.

GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...